Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study of Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases

NCT04832204 is registered in ClinicalTrials.gov with Beijing Hospital as lead sponsor.

NCT NCT04832204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04832204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study of Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases
Lead sponsor
Beijing Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
March 25, 2021
Completion date
April 30, 2024
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor